NASDAQ:TPTX

Turning Point Therapeutics Stock Forecast, Price & News

$77.68
+2.75 (+3.67 %)
(As of 06/14/2021 04:40 PM ET)
Add
Compare
Today's Range
$74.19
$77.81
50-Day Range
$62.93
$89.95
52-Week Range
$54.43
$141.30
Volume605,252 shs
Average Volume387,000 shs
Market Capitalization$3.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.98
30 days | 90 days | 365 days | Advanced Chart
Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Turning Point Therapeutics logo

About Turning Point Therapeutics

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

368th out of 2,100 stocks

Pharmaceutical Preparations Industry

173rd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

Is Turning Point Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Turning Point Therapeutics stock.
View analyst ratings for Turning Point Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Turning Point Therapeutics?

Wall Street analysts have given Turning Point Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Turning Point Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Turning Point Therapeutics
.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) issued its earnings results on Wednesday, May, 5th. The company reported ($0.73) EPS for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.15. The firm had revenue of $25.21 million for the quarter, compared to analysts' expectations of $25 million.
View Turning Point Therapeutics' earnings history
.

How has Turning Point Therapeutics' stock price been impacted by Coronavirus?

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 91.6% and is now trading at $77.68.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TPTX?

7 analysts have issued 1 year price targets for Turning Point Therapeutics' stock. Their forecasts range from $127.00 to $186.00. On average, they expect Turning Point Therapeutics' stock price to reach $153.71 in the next year. This suggests a possible upside of 97.9% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the following people:
  • Dr. Athena Maria Countouriotis, Pres, CEO, Director & Interim Principal Financial Officer (Age 49, Pay $1.13M)
  • Dr. Siegfried Reich, Exec. VP & Chief Scientific Officer (Age 61, Pay $577.1k)
  • Ms. Annette C. North Esq., LLB, Exec. VP, Gen. Counsel & Company Sec. (Age 55, Pay $641.8k)
  • Mr. Andrew John Partridge, Exec. VP & Chief Commercial Officer (Age 52, Pay $979.04k)
  • Ms. Kyri k. Van Hoose, VP of Accounting & Interim Principal Accounting Officer
  • Mr. Ed Gemo, Sr. VP & Chief Information Officer
  • Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
  • Ms. Heather Adams, VP of HR
  • Dr. Jeffrey P. Whitten, Sr. VP of Pre-Clinical Devel.
  • Dr. K. C. Lim Pharm.D., Sr. VP of Clinical Operations & Regulatory Affairs

Who are some of Turning Point Therapeutics' key competitors?

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), The Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.47%), Cormorant Asset Management LP (5.59%), Price T Rowe Associates Inc. MD (5.13%), Orbimed Advisors LLC (4.80%), Lord Abbett & CO. LLC (2.25%) and Alliancebernstein L.P. (2.15%). Company insiders that own Turning Point Therapeutics stock include Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mohammad Hirmand, Siegfried Reich, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics
.

Which institutional investors are selling Turning Point Therapeutics stock?

TPTX stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Lord Abbett & CO. LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Goldman Sachs Group Inc., Atom Investors LP, Parkman Healthcare Partners LLC, and Morgan Stanley. Company insiders that have sold Turning Point Therapeutics company stock in the last year include Annette North, Athena Countouriotis, Brian Lee Baker, Mohammad Hirmand, Siegfried Reich, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Turning Point Therapeutics stock?

TPTX stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Cormorant Asset Management LP, D. E. Shaw & Co. Inc., Federated Hermes Inc., Logos Global Management LP, Alliancebernstein L.P., Renaissance Technologies LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Simeon George, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $77.68.

How much money does Turning Point Therapeutics make?

Turning Point Therapeutics has a market capitalization of $3.82 billion and generates $25 million in revenue each year. The company earns $-157,290,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis.

How many employees does Turning Point Therapeutics have?

Turning Point Therapeutics employs 169 workers across the globe.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Where are Turning Point Therapeutics' headquarters?

Turning Point Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.